Kiniksa Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results and Recent Portfolio Execution

About this update from Kiniksa Pharmaceuticals International, Plc

[{"type":"text","content":"– ARCALYST® (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively – – ARCALYST full-year 2023 net product revenue expected to be $190 - $205 million, representing >60% year-over-year growth at the midpoint – – ARCALYST average total duration of therapy as of the end of Q4 2022 was ~18 months after accounting for patient restarts – – Cash reserves expected to fund operations into at least 2025 – HAMILTON, Bermuda, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a pipeline of immune-modulating assets designed to target a spectrum of cardiovascular and autoimmune diseases, today reported fourth quarter and full-year 2022 financial results and recent portfolio execution. “Kiniksa executed across its cardiovascular and emerging autoimmune franchises in 2022,” said Sanj K. Patel, Chairman and Chief Executive Officer of Kiniksa. “Within the cardiovascular franchise, we are focused on increasing brand awareness of ARCALYST, the only FDA-approved treatment for recurrent pericarditis, and pursuing collaborative study agreements for mavrilimumab in rare cardiovascular diseases. In our emerging autoimmune franchise, we believe KPL-404, our CD40 antagonist, has significant potential for differentiation in targeting chronic autoimmune diseases. We are advancing the Phase 2 trial of KPL-404 in rheumatoid arthritis into the efficacy portion and expect data in the first half of 2024. Additionally, our profitable ARCALYST collaboration, non-dilutive capital from strategic out-licensing transactions, and continued financial discipline support these efforts while providing cash runway into at least 2025.” Portfolio ExecutionARCALYST (IL-1α and IL-1β cytokine trap) ARCALYST net product revenue was $39.9 million and $122.5 million for the fourth quarter and full-year 2022, respectively.Since launch, greater than 800 prescribers have written ARCALYST prescriptions for recurrent pericarditis, with 22% having written prescriptions for 2 or more patients.As of the end of the fourth quarter of 2022, there was a greater than 90% payer approval rate of completed patient cases for recurrent pericarditis.As of the end of the fourth quarter of 2022, ARCALYST average total duration of therapy was approximately 18 months after accoun...

More updates from Kiniksa Pharmaceuticals International, Plc